Total Payments
$3.1M
2024 Payments
$395,521
Companies
33
Transactions
3,556
Medicare Patients
10,959
Medicare Billing
$4.6M
Payment Breakdown by Category
Other$2.3M (72.5%)
Travel$415,658 (13.2%)
Consulting$374,988 (11.9%)
Food & Beverage$65,273 (2.1%)
Research$7,613 (0.2%)
Education$101.37 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $1.8M | 820 | 56.5% |
| Honoraria | $505,048 | 199 | 16.1% |
| Travel and Lodging | $415,658 | 1,197 | 13.2% |
| Consulting Fee | $374,988 | 155 | 11.9% |
| Food and Beverage | $65,273 | 1,158 | 2.1% |
| Unspecified | $7,613 | 13 | 0.2% |
| Education | $101.37 | 14 | 0.0% |
Payments by Type
General
$3.1M
3,543 transactions
Research
$7,613
13 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| ABBVIE INC. | $681,925 | 857 | $0 (2024) |
| Janssen Scientific Affairs, LLC | $311,452 | 277 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $304,858 | 273 | $0 (2024) |
| Horizon Therapeutics plc | $290,395 | 250 | $0 (2023) |
| Horizon Pharma plc | $275,171 | 229 | $0 (2018) |
| Janssen Biotech, Inc. | $206,369 | 225 | $0 (2024) |
| Regeneron Healthcare Solutions, Inc. | $205,497 | 262 | $0 (2019) |
| UCB, Inc. | $188,283 | 291 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $162,276 | 228 | $0 (2024) |
| GENZYME CORPORATION | $155,257 | 165 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $395,521 | 480 | AstraZeneca Pharmaceuticals LP ($86,966) |
| 2023 | $406,119 | 477 | Janssen Biotech, Inc. ($93,112) |
| 2022 | $416,354 | 422 | AstraZeneca Pharmaceuticals LP ($122,886) |
| 2021 | $272,300 | 275 | AbbVie Inc. ($68,630) |
| 2020 | $306,504 | 271 | AbbVie Inc. ($89,773) |
| 2019 | $474,811 | 527 | AbbVie, Inc. ($115,630) |
| 2018 | $484,346 | 589 | Horizon Pharma plc ($153,734) |
| 2017 | $389,344 | 515 | Horizon Pharma plc ($121,438) |
All Payment Transactions
3,556 individual payment records from CMS Open Payments — Page 1 of 143
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/20/2024 | GENZYME CORPORATION | KEVZARA (Biological) | Consulting Fee | Cash or cash equivalent | $1,849.00 | General |
| Category: Rheumatology | ||||||
| 12/19/2024 | AstraZeneca Pharmaceuticals LP | SAPHNELO (Biological) | Travel and Lodging | In-kind items and services | $1,367.94 | General |
| Category: Inflammation and Autoimmunity | ||||||
| 12/19/2024 | E.R. Squibb & Sons, L.L.C. | — | Consulting Fee | Cash or cash equivalent | $1,200.00 | General |
| 12/19/2024 | AstraZeneca Pharmaceuticals LP | SAPHNELO (Biological) | Travel and Lodging | In-kind items and services | $272.02 | General |
| Category: Inflammation and Autoimmunity | ||||||
| 12/19/2024 | AstraZeneca Pharmaceuticals LP | SAPHNELO (Biological) | Food and Beverage | In-kind items and services | $135.00 | General |
| Category: Inflammation and Autoimmunity | ||||||
| 12/19/2024 | AstraZeneca Pharmaceuticals LP | SAPHNELO (Biological) | Travel and Lodging | In-kind items and services | $68.18 | General |
| Category: Inflammation and Autoimmunity | ||||||
| 12/19/2024 | AstraZeneca Pharmaceuticals LP | SAPHNELO (Biological) | Food and Beverage | In-kind items and services | $23.65 | General |
| Category: Inflammation and Autoimmunity | ||||||
| 12/18/2024 | AstraZeneca Pharmaceuticals LP | — | Consulting Fee | Cash or cash equivalent | $1,611.00 | General |
| 12/17/2024 | UCB, Inc. | Bimzelx (Biological) | Consulting Fee | Cash or cash equivalent | $10,650.00 | General |
| Category: Immunology | ||||||
| 12/17/2024 | AstraZeneca Pharmaceuticals LP | SAPHNELO (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,300.00 | General |
| Category: Inflammation and Autoimmunity | ||||||
| 12/17/2024 | Janssen Scientific Affairs, LLC | TREMFYA (Drug) | Travel and Lodging | Cash or cash equivalent | $275.00 | General |
| Category: Immunology | ||||||
| 12/17/2024 | UCB, Inc. | Bimzelx (Biological) | Food and Beverage | Cash or cash equivalent | $97.97 | General |
| Category: Immunology | ||||||
| 12/17/2024 | UCB, Inc. | Bimzelx (Biological) | Travel and Lodging | Cash or cash equivalent | $64.00 | General |
| Category: Immunology | ||||||
| 12/17/2024 | Janssen Scientific Affairs, LLC | TREMFYA (Drug) | Travel and Lodging | Cash or cash equivalent | $36.18 | General |
| Category: Immunology | ||||||
| 12/17/2024 | UCB, Inc. | Bimzelx (Biological) | Travel and Lodging | Cash or cash equivalent | $36.18 | General |
| Category: Immunology | ||||||
| 12/17/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $15.67 | General |
| Category: IMMUNOLOGY | ||||||
| 12/17/2024 | Janssen Scientific Affairs, LLC | TREMFYA (Drug) | Travel and Lodging | Cash or cash equivalent | $8.92 | General |
| Category: Immunology | ||||||
| 12/17/2024 | UCB, Inc. | Bimzelx (Biological) | Food and Beverage | Cash or cash equivalent | $5.53 | General |
| Category: Immunology | ||||||
| 12/16/2024 | GENZYME CORPORATION | KEVZARA (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $7,696.00 | General |
| Category: Rheumatology | ||||||
| 12/16/2024 | ABBVIE INC. | RINVOQ (Biological) | Consulting Fee | Cash or cash equivalent | $900.00 | General |
| Category: IMMUNOLOGY | ||||||
| 12/16/2024 | UCB, Inc. | Bimzelx (Biological) | Food and Beverage | In-kind items and services | $27.96 | General |
| Category: Immunology | ||||||
| 12/16/2024 | E.R. Squibb & Sons, L.L.C. | ORENCIA (Biological) | Education | In-kind items and services | $5.78 | General |
| Category: Immunology | ||||||
| 12/13/2024 | ABBVIE INC. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $33.22 | General |
| Category: IMMUNOLOGY | ||||||
| 12/12/2024 | AstraZeneca Pharmaceuticals LP | SAPHNELO (Biological) | Travel and Lodging | In-kind items and services | $246.50 | General |
| Category: Inflammation and Autoimmunity | ||||||
| 12/12/2024 | AstraZeneca Pharmaceuticals LP | SAPHNELO (Biological) | Travel and Lodging | In-kind items and services | $137.02 | General |
| Category: Inflammation and Autoimmunity | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| ADALIMUMAB PFIZER CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $3,200 | 1 |
| High Serum IL-6 Predicts Differential Response Between Sarilumab and Adalimumab or MTX | SANOFI-AVENTIS U.S. LLC | $1,469 | 2 |
| High baseline serum IL-6 identifies a subgroup of rheumatoid arthritis patients with rapid joint damage and clinical progression and predicts sarilumab treatment response | SANOFI-AVENTIS U.S. LLC | $804.00 | 1 |
| Elevated serum baseline IL-6 differentiates sarilumab and adalimumab treatment response: a precision medicine approach to aid in selection of treatments | SANOFI-AVENTIS U.S. LLC | $444.48 | 1 |
| High baseline serum IL-6 identifies a subgroup of RA patients with rapid progression of joint damage and clinical progression in RA and predicts sarilumab treatment response | SANOFI-AVENTIS U.S. LLC | $444.48 | 1 |
| High serum interleukin-6 is associated with severe progression of rheumatoid arthritis and increased treatment response differentiating sarilumab from methotrexate or adalimumab | SANOFI-AVENTIS U.S. LLC | $359.90 | 2 |
| A Randomized, Double-blind, Parallel-group Study Assessing the Efficacy and Safety of Sarilumab Monotherapy Versus Adalimumab Monotherapy in Patients With Rheumatoid Arthritis | SANOFI-AVENTIS U.S. LLC | $318.00 | 1 |
| Gout remission: perceptions of rheumatologist, nephrologist, and primary care physicians | Amgen Inc. | $260.00 | 1 |
| The concept of gout remission as viewed by rheumatologists, nephrologists, and primary care physicians | Amgen Inc. | $257.64 | 1 |
| A randomized, double-blind, placebo-controlled, multicenter, two-part, dose ranging and confirmatory study with an operationally seamless design, evaluating efficacy and safety of SAR153191 on top of | SANOFI-AVENTIS U.S. LLC | $28.00 | 1 |
| High Serum Interleukin-6 is Associated With Severe Progression of Rheumatoid Arthritis and Increased Treatment Response Differentiating Sarilumab from Adalimumab or Methotrexate in a Post Hoc Analysis | SANOFI-AVENTIS U.S. LLC | $28.00 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 57 | 3,312 | 84,516 | $3.9M | $1.3M |
| 2022 | 54 | 3,481 | 103,435 | $4.1M | $1.3M |
| 2021 | 55 | 3,450 | 89,392 | $3.7M | $1.4M |
| 2020 | 19 | 716 | 14,897 | $2.2M | $596,772 |
Total Patients
10,959
Total Services
292,240
Medicare Billing
$4.6M
Procedure Codes
185
All Medicare Procedures & Services
185 procedure records from CMS Medicare Utilization — Page 1 of 8
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J0129 | Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | Office | 2023 | 57 | 11,250 | $787,500 | $375,441 | 47.7% |
| J3262 | Injection, tocilizumab, 1 mg | Office | 2023 | 18 | 30,600 | $336,600 | $143,191 | 42.5% |
| J1745 | Injection, infliximab, excludes biosimilar, 10 mg | Office | 2023 | 50 | 5,420 | $635,580 | $141,215 | 22.2% |
| J9312 | Injection, rituximab, 10 mg | Office | 2023 | 13 | 2,030 | $304,500 | $128,654 | 42.3% |
| J1602 | Injection, golimumab, 1 mg, for intravenous use | Office | 2023 | 29 | 11,250 | $562,500 | $118,531 | 21.1% |
| J0897 | Injection, denosumab, 1 mg | Office | 2023 | 70 | 6,420 | $269,640 | $116,326 | 43.1% |
| J3111 | Injection, romosozumab-aqqg, 1 mg | Office | 2023 | 12 | 12,390 | $309,750 | $97,993 | 31.6% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 189 | 472 | $169,920 | $46,276 | 27.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 215 | 346 | $86,500 | $30,550 | 35.3% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 119 | 166 | $52,124 | $20,740 | 39.8% |
| 96401 | Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | Office | 2023 | 82 | 356 | $62,300 | $19,548 | 31.4% |
| 82306 | Vitamin d-3 level | Office | 2023 | 153 | 203 | $32,277 | $5,848 | 18.1% |
| 96415 | Administration of chemotherapy into vein, each additional hour | Office | 2023 | 59 | 246 | $30,750 | $5,276 | 17.2% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 29 | 29 | $10,991 | $4,630 | 42.1% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 62 | 70 | $12,530 | $4,358 | 34.8% |
| 86235 | Measurement of antibody for assessment of autoimmune disorder, any method | Office | 2023 | 33 | 210 | $20,370 | $3,690 | 18.1% |
| 76881 | Complete ultrasound scan of joint | Office | 2023 | 35 | 85 | $20,400 | $3,579 | 17.5% |
| 86481 | Tuberculosis test, enumeration of t-cells | Office | 2023 | 36 | 36 | $11,808 | $3,528 | 29.9% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2023 | 247 | 379 | $14,402 | $2,853 | 19.8% |
| 77080 | Dxa bone density measurement of hip, pelvis, spine | Office | 2023 | 73 | 74 | $27,750 | $2,667 | 9.6% |
| 77089 | Calculation of trabecular bone score (tbs) using imaging data with interpretation and report on fracture risk | Office | 2023 | 89 | 90 | $10,530 | $2,647 | 25.1% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 185 | 273 | $6,825 | $2,293 | 33.6% |
| 83970 | Parathormone (parathyroid hormone) level | Office | 2023 | 44 | 49 | $11,662 | $1,982 | 17.0% |
| 96375 | Injection of additional new drug or substance into vein | Office | 2023 | 42 | 136 | $11,152 | $1,596 | 14.3% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 31 | 31 | $7,378 | $1,352 | 18.3% |
About Dr. Gordon Lam, MD
Dr. Gordon Lam, MD is a Rheumatology healthcare provider based in Charlotte, North Carolina. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 01/30/2007. The National Provider Identifier (NPI) number assigned to this provider is 1750427308.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Gordon Lam, MD has received a total of $3.1M in payments from pharmaceutical and medical device companies, with $395,521 received in 2024. These payments were reported across 3,556 transactions from 33 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($1.8M).
As a Medicare-enrolled provider, Lam has provided services to 10,959 Medicare beneficiaries, totaling 292,240 services with total Medicare billing of $4.6M. Data is available for 4 years (2020–2023), covering 185 distinct procedure/service records.
Ad
Practice Information
- Specialty Rheumatology
- Location Charlotte, NC
- Active Since 01/30/2007
- Last Updated 01/02/2026
- Taxonomy Code 207RR0500X
- Entity Type Individual
- NPI Number 1750427308
Products in Payments
- KRYSTEXXA (Biological) $330,020
- SAPHNELO (Biological) $291,909
- KRYSTEXXA (Drug) $275,171
- RINVOQ (Biological) $240,314
- SIMPONI ARIA (Biological) $228,166
- KEVZARA (Biological) $184,553
- Humira (Biological) $143,882
- STELARA (Biological) $143,222
- BENLYSTA (Biological) $134,278
- KEVZARA SARILUMAB INJECTION (Biological) $118,941
- TREMFYA (Drug) $108,653
- XELJANZ (Drug) $91,915
- ORENCIA (Biological) $83,025
- RINVOQ (Drug) $74,023
- KEVZARA (Drug) $55,100
- Rinvoq (Biological) $40,808
- SKYRIZI (Biological) $33,104
- LUPKYNIS (Drug) $23,510
- Bimzelx (Biological) $17,156
- Cimzia (Drug) $14,465
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Rheumatology Doctors in Charlotte
Dr. Andrew Laster, Md, MD
Rheumatology — Payments: $751,361
Rheumatology $751,361
Dr. Heather Gladue, Do, DO
Rheumatology — Payments: $207,205
Rheumatology $207,205
Firas Kassab, M.d, M.D
Rheumatology — Payments: $71,224
Rheumatology $71,224
Dr. Alireza Nami, M.d, M.D
Rheumatology — Payments: $56,705
Rheumatology $56,705
John Brendese, M.d., Facr, M.D., FACR
Rheumatology — Payments: $21,513
Rheumatology $21,513
Dr. Ashley Toci, M.d, M.D
Rheumatology — Payments: $8,229
Rheumatology $8,229